Responses cited increasing workloads, shrinking autonomy, mounting interference from hospital administrators and insurance ...

ICE raids are disrupting worksites across the country, particularly construction sites, as President Trump’s mass deportation ...

Calling the Iranian regime "evil," Belgium's prime minister reluctantly endorsed the notion of a regime change in Tehran on ...

On June 26, Pfizer announced positive topline results from its Phase 3 BASIS study evaluating HYMPAVZI (marstacimab) for ...

Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% ...

Javed Akhtar defends Diljit Dosanjh amid backlash over Pakistani actress Hania Aamir's casting in ‘Sardaar Ji 3’. He urges a ...

The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with ...

Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and ...

Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its ...

Pfizer PFE announced that the phase III BASIS study evaluating its anti-TFPI inhibitor Hympavzi (marstacimab) for treating ...

Pfizer said on Thursday its hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain ...

Pfizer said a late-stage study of its Hympavzi hemophilia drug met its key goals in patients with the blood-clotting disorder who have inhibitors that can render some treatments ineffective.